Replies to post #166465 on Anavex Life Sciences Corp (AVXL)

[Kentucky123]

It appears that someone wants the dots to be connected and take their foot off the neck of AVXL. Probably the same people who have put it there in the first place. The science language is difficult for me to understand but even a non scientist like me can connect some dots. The share price must increase at some point for AVXL and for the poor sufferers of CNS diseases.

[powerwalker]

Bio, sokol and other Anavex/Biogen watchers:

To me, Biogen knows it is sitting on a 2-73 mother lode that will overthrow all other therapies in the CNS fields but doesn't know how to proceed.

I think Biogen has used 2-73 in combo with its MS drugs and in a MS mono-therapy with some of its human trial participants and is waiting to determine if its (2-73) efficacy fades over time. It won't!

It is the only explanation for the two year period of testing. No company at this stage of 2-73's development would spend TWO YEARS with petri dishes and mice trials! [Other than F1, most of us believe 2-73 is a safe drug.]

While TGD's price is high for Biogen on a partnership basis, once the public is made aware of previous unheard of benefits from 2-73 in MS treatment, the 10 figure price tag for a partnership will be understood by Biogen's s/holders ... unless Roche goes to 11 figures!


Anavex Now ... Mono-style!!!

[jimmy_mcyoloswag]

Guys, could it be that sigmaR1 activation and subsequent coupling of mitochondria is basically needed for mitochindria to hitch a ride and be transported down the distant axonal tracks of neurons? Pathophysiological failure of this train system leads to breakdown of synaptic transmission, demyelination and axon degeneration. Depending on which neuron type is affected we call it DM, AD, PD, MS, ALS, AMS, Chronic pain...